Abstract
Objectives We investigated ERP29 gene role on pharynx squamous cell carcinoma (PSCC) progression in cisplatin (CDDP)-sensitive (FaDu and LAU-2063), CDDP-treated (FaDu-CDDP), and CDDP-resistant (FaDu-R) cells.
Materials and Methods Cells, modified to induce ERP29 overexpression or silencing, were mainly submitted to cell proliferation, necrosis, and migration assay. E-cadherin immunoexpression was assessed in three-dimensional spheroids. WNT, MAPK, and PI3K/AKT pathways genes’ expression were identified by PCR array and validated by qPCR. The influence of microRNA miR-4421 inhibitor on ERP29 expression, and its target genes, were quantified by qPCR.
Results ERP29 silencing especially decreased necrotic cell death and increased migration in CDDP-sensitive, treated, and resistant cells, and decreased E-cadherin immunoexpression in CDDP-sensitive three-dimensional-spheroids. During CDDP treatment, ERP29 silencing increased cell proliferation. In CDDP-sensitive cells, ERP29 silencing increased the expression of several genes involved in WNT, MAPK, and PI3K/AKT pathways and decreased CASP9 expression. During CDDP treatment, ERP29 silencing decreased MDM2 and CASP9 expression. In CDDP-resistant cells, ERP29 silencing increased SOS1, MAPK1, AKT1, ITGAV, and CCNE1; and decreased KRAS, JUN, MDM2, and CASP9 expression. In addition, miR-4421 inhibition increased ERP29 expression and decreased MAPK1, AKT1, and JUN expression in CDDP-sensitive cells; and SOS1, MAPK1, AKT1, and ITGAV in CDDP-resistant cells, suggesting a potential therapeutic use for miR-4421 inhibitor.
Conclusions ERP29 silencing seems to decrease necrosis and increase migration of PSCC cells by modulating genes enrolled in WNT, MAPK, and PI3K/AKT pathways. Once validated, our data may enable target therapy development based on ensuring ERP29 expression that could benefit patients with CDDP-sensitive and resistant tumors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the National Council for Scientific and Technological Development (CNPq) process n. 140019/2020-0 and n. 307944/2022-0).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
LAU-2063 cell line CDDP-sensitive was established from hypopharyngeal squamous cell carcinoma obtained from a male patient undergoing surgery at the Lausanne University Hospital (CHUV) under protocol approved by the Cantonal Department of the Swiss Ethics Committees
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.